In the field of therapeutic discovery and development for complex conditions, the creation of accurate and reliable disease models is crucial for understanding disease mechanisms and evaluating potential therapeutics. Our company is dedicated to offering cutting-edge disease model development services to tackle the challenges presented by intricate diseases.
Overview of Rare Skin Disease Model Development
Significant progress has been made in skin disease models across various levels in recent years. Optimization of animal models has enhanced their applicability in studying human skin pathology. Advances in cell models, particularly through the use of gene editing technologies, have enabled more precise replication of disease mechanisms at the cellular level.
Fig.1 Different skin tissue culture and engineering platforms used in the skin drug discovery process. (Imran, M.,
et al., 2024)
Furthermore, organoid 3D models have achieved new heights in simulating the real skin microenvironment, with technologies like skin-on-a-chip and spheroids maturing to facilitate efficient drug screening and toxicity testing. These innovations have greatly improved the accuracy and applicability of rare skin disease research, providing new opportunities for drug discovery and therapeutic development.
Types of Rare Skin Disease Models
2D Cell Models
2D cell models utilize monolayer cultures of specific skin cell types, allowing researchers to study disease mechanisms and cell interactions in a highly controlled environment. Despite their simplicity and ease of manipulation, these models are instrumental for initial drug screening and identifying cell-specific therapeutic targets.
3D Models
3D models, such as organoids and bioprinted skin constructs, address the limitations of 2D cell models by creating a complex microenvironment that more closely mimics human skin. These models offer tissue complexity and cellular diversity, enabling researchers to investigate more realistic cellular behaviors, pathophysiology, and drug responses.
Animal Models
Animal models, particularly rodents genetically or chemically induced with rare skin diseases, provide a systemic understanding of disease progression and mechanisms. They are indispensable tools for studying pathology development, immune responses, and assessing the efficacy and safety of potential new therapies.
In Vitro and In Vivo Skin Disease Models
To promote the advancement of skin drug development and discovery, a variety of in vitro and In Vivo skin models have been created that closely replicate human disease scenarios. These models serve as viable alternatives to animal testing, enabling researchers to investigate drug permeability and toxicity, while also enhancing the understanding of disease mechanisms.
Table1. Commercially available skin models to study and understand skin and skin-related drug discovery. (Imran, M., et al., 2024)
| Model |
Characteristics |
Applications |
| SkinEthic RHE |
Normal keratinocytes cultured on an inert polycarbonate filter to form human epidermis. |
UV exposure, skin irritation, DNA damage, and permeability testing. |
| T-skin |
Human full-thickness skin containing keratinocytes/ fibroblasts |
UV exposure, skin irritation, DNA damage, permeability test |
| SkinEthic RHE-LC |
Epidermal model with Langerhans cell progenitors |
Skin immune response, UV exposure, omics analysis, permeability testing |
| EpiDerm FT |
Human full-thickness skin containing keratinocytes/ fibroblasts |
Antiaging, wound healing, skin hydration, anti-UV efficiency products |
| EPIDerm |
Normal highly differentiated keratinocytes with RHE model |
Skin corrosion and irritation test, phototoxicity |
| Melanoma |
Malignant melanoma cells, fibroblasts/keratinocytes |
Antimelanoma drug screening and tumor invasion |
| Epicutaneous Sensitization Model |
ES-sensitized mice manifest increased scratching behavior with developing epidermal hyperplasia. |
It can mimic the dysfunction barrier of AD. |
| Squamous Cell Carcinoma Model |
Transgenic expression of ErbB2, Src, Fyn, and MEK-1 kinases driven by keratin promoters in epidermis spontaneously produce cutaneous SCC |
Researching cancer pathogenesis, testing potential treatments |
Our Services
At our company, we are dedicated to delivering a comprehensive range of services to advance the development of disease models for rare skin diseases. Our team of expert scientists and researchers employs cutting-edge technologies and extensive expertise to drive your model development projects, ensuring accuracy and innovation throughout every phase of creation.
Our Rare Skin Disease Model Development Services
3D Models Development Services
- 3D Bioprinting Models
- Skin-on-A-Chip Models
- Reconstructed Skin
- Spheroids
- Microfluidic Cell Culture
- Organoid Models
Animal Models Development Services
- Genetically Engineering Model
- Induced Disease Model
- Humanized Animal Model
- Syngeneic Model
- Xenograft Model
Types of Rare Skin Diseases
Leveraging our extensive expertise, our distinguished organization provides a wide array of therapy development services from multiple perspectives, meticulously tailored to meet your individual needs. With our abundant experience, we are fully capable of tackling various aspects of therapy development, delivering thorough and personalized solutions.
Why Choose Us?
Professional core technical team.
Advanced experimental equipment.
Empowering success through cooperation.
Strict quality control system.
At our company, we are dedicated to offering extensive, one-stop preclinical development services, encompassing everything from disease model development to innovative therapy research. If you are interested in our services, please don't hesitate to contact us.
References
- Imran, M., et al. "Advances in, and Prospects of, 3d Preclinical Models for Skin Drug Discovery." Drug Discov Today (2024): 104208.
- Stanton, D. N., et al. "Bioengineered Efficacy Models of Skin Disease: Advances in the Last 10 Years." Pharmaceutics 14.2 (2022).
All of our services and products are intended for preclinical research use
only and cannot be used to diagnose, treat or manage patients.
